'Gene correction' presentation slideshows

GENE THERAPY

GENE THERAPY. In humans. Cancer 69%. The Food and Drug Administration (FDA) has not yet approved any human gene therapy product for sale. 2) Immune response . It reduces gene therapy effectiveness and makes repetitive rounds of gene therapy useless.

1.1k views • 18 slides

I-SceI-mediated Genome Editing in the Canine Model

259 views • 15 slides

gfp -

Gene correction in trans: a model for gene therapy. gfp -. Luther Davis Jason Cummings Nancy Maizels. Gene correction in trans: a model for gene therapy. GFP +. Luther Davis Jason Cummings Nancy Maizels. nuclease. Gene correction in trans. Cut sites. eGFP. Poly-lacO. Puro. trGFP.

279 views • 10 slides

Optimizing efficiency and safety of targeted gene correction

Optimizing efficiency and safety of targeted gene correction. NHEJ. Cleave or nick. religation in situ. Homology-directed repair. 25 20 15 10 5 0. 21-fold. Foci per nucleus. 0.4 21 1. ?- H2AX foci induced by cleavase but not nickase. Merge/DAPI. ?- H2AX. -.

163 views • 8 slides

Aim 2. Are nicks efficient and safe initiating sites for targeted gene correction?

Aim 2. Are nicks efficient and safe initiating sites for targeted gene correction?. NHEJ G1 phase. homology-directed repair S phase. DSBs can cause translocations. Merge/DAPI. ?- H2AX. 25 20 15 10 5 0. 21-fold. Foci per nucleus. -. 0.4 21 1. I-AniI

164 views • 3 slides